UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 22, 2007

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[ ] Written communication pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 5.02

Departure of Directors or Certain Officers; Election of

Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

On August 7, 2007, the Board of Directors

of Pfizer Inc. (the "Company") elected Frank A. D'Amelio Senior

Vice President and Chief Financial Officer of the Company and appointed

Mr. D'Amelio a member of the Company's Executive Leadership Team effective

September 10, 2007 (the "Effective Date"), subject to the Company

reaching appropriate agreement with Mr. D'Amelio regarding his acceptance

of such positions. On August 22, 2007, Mr. D'Amelio agreed to accept such

positions with the Company as of the Effective Date. A copy of the press

release announcing the election and appointment of Mr. D'Amelio is attached

hereto as Exhibit 99 and is incorporated herein by reference.

Prior to joining the Company, Mr. D'Amelio,

49, served as Chief Administrative Officer and Senior Executive Vice President

Integration of Alcatel-Lucent since December 2006; Chief Operating Officer

of Lucent Technologies from January 2006 through November 2006; and Executive

Vice President, Administration, and Chief Financial Officer of Lucent

Technologies from May 2001 until January 2006. Mr. D'Amelio began his

career in 1979 at Bell Labs, where he held a variety of financial, accounting

and general management positions. Mr. D'Amelio earned a bachelor's degree

in Accounting from St. Peter's College and an MBA in Finance from St.

John's University.

There are no arrangements or understandings

between Mr. D'Amelio and any other persons pursuant to which Mr. D'Amelio

was selected as an officer. Neither Mr. D'Amelio nor any member of his

immediate family has been since January 1, 2006 or is a party, directly

or indirectly, to any transaction or currently proposed transaction required

to be reported pursuant to Item 404(a) of Regulation S-K.

Mr. D'Amelio offer of employment provides

for the following compensatory arrangements:

- Sign-on payment: A one-time sign-on payment of

$1,000,000 payable in March 2008, if Mr. D'Amelio is employed by the

Company through the end of 2007.

- Salary: An initial annual base salary of $1,026,000.

- Bonus: A target bonus under the Company's annual

incentive plan equal to 80% of his base salary, with his 2007 bonus

being pro-rated for the period he is employed by the Company in 2007.

- Long-term incentive compensation: An executive

long-term incentive compensation award with a target value of $3.5

million, also pro-rated for the period he is employed by the Company

in 2007. Half of the value of this award will be paid in the form

of stock options, 25% in the form of restricted stock units (RSUs)

and 25% in the form of performance shares.

In addition, in order to replace certain

compensation and benefits forfeited by Mr. D'Amelio due to his termination

from Alcatel-Lucent, the Company will provide Mr. D'Amelio with the following:

- Replacement cash compensation: $2,700,000

in additional cash compensation payable no later than thirty calendar

days after the Effective Date.

- Replacement equity compensation: (i) 233,600 RSUs

("Replacement RSUs"), one-third of which will vest on the

last day of the month of each of the first three anniversaries of

the Effective Date if Mr. D'Amelio is employed by the Company on each

such vesting day, and (ii) 292,000 stock options, which will vest

on the same schedule as the Replacement RSUs. If Mr. D'Amelio voluntarily

terminates his employment without good reason (as defined in the severance

agreement described below) after the last day of the month in which

the first anniversary of the Effective Date occurs and prior to the

second anniversary of the Effective Date, he will be required to pay

to the Company an amount equal to the fair market value, determined

on an after-tax basis, of the shares of Common Stock issued to him

with respect to the Replacement RSUs that vested prior to such termination.

- Replacement pension benefit: An additional retirement

benefit reflecting six years of additional pension service credit

under the Company's Unfunded Supplemental Retirement Plan and Retirement

Annuity Plan will be provided in accordance with the terms and conditions

specified in the letter regarding Mr. D'Amelio's replacement pension

benefit dated August 22, 2007. A copy of the letter regarding Mr.

D'Amelio's replacement pension benefit is attached hereto as Exhibit

10.1.

Additional information about the Company's

annual incentive plan, executive long-term incentive compensation awards,

retirement plans and other executive compensation, benefit and perquisite

arrangements is available in the Company's Definitive Proxy Statement

filed with the Securities and Exchange Commission on March 15, 2007 (the

"Proxy Statement").

Severance Agreement: On August 22, 2007,

the Company entered into a severance agreement with Mr. D'Amelio which

will become effective as of the Effective Date. Under the terms of the

severance agreement, if at any time prior to the second anniversary of

the Effective Date, Mr. D'Amelio's employment is terminated by the Company

without cause or by Mr. D'Amelio for good reason (as those terms are defined

in the agreement), Mr. D'Amelio will be entitled to receive a lump sum

payment equal to the sum of: (i) his earned but unpaid base salary through

the date of termination, and (ii) a pro-rated portion of the greater of

his target or earned annual incentive award for the year in which the

termination occurs. In addition, he will be entitled to receive a lump

sum amount equal to (i) two full years' base salary, plus (ii) two times

the greater of his target or earned annual incentive award for the year

of termination. For the two year period following such a termination (or,

if earlier, until Mr. D'Amelio becomes eligible to receive group health

coverage from another employer), Mr. D'Amelio will continue to receive

group health benefits from the Company at the Company's expense (or shall

be paid the cash equivalent thereof). The payments and benefits provided

under the severance agreement will be reduced by any payments and benefits

payable to Mr. D'Amelio as a result of termination of his employment following

a change in control of the Company that occurs during the term of the

severance agreement. Under the terms of the severance agreement, Mr. D'Amelio

will be subject to certain confidentiality and non-disparagement provisions

and, during his employment and for a period of 12 months thereafter, certain

non-compete and non-solicitation provisions. A copy of the severance agreement

between the Company and Mr. D'Amelio dated August 22, 2007 is attached

hereto as Exhibit 10.2.

Standard Form Change-in-Control and Indemnification

Agreements: On the Effective Date, the Company will enter into its standard

form change-in-control severance agreement, as amended, for named executive

officers (the "Change-in-Control Severance Agreement") with

Mr. D'Amelio. A description of the material terms of the Change-in-Control

Severance Agreement is contained in the Proxy Statement. On the Effective

Date, the Company also will enter into its standard form indemnification

agreement for elected officers with Mr. D'Amelio. Under the terms of the

indemnification agreement and subject to the conditions specified therein,

Mr. D'Amelio will be entitled to the advancement of expenses by the Company

and to indemnification by the Company against expenses, judgments, penalties,

fines and amounts paid in settlement in the event that he is, or is threatened

to be made, a party to any legal proceeding by reason of his status as

an officer of the Company.

On August 22, 2007, the Company made the

following changes to the compensation arrangements of Ian C. Read, the

Company's Senior Vice President and President, Worldwide Pharmaceutical

Operations:

- Salary: Increased Mr. Read's base salary from

$920,000 to $1,026,000.

- Target bonus: Increased Mr. Read's target bonus

under the Company's annual incentive plan from 75% to 80% of base

salary.

- Long-term incentive compensation: Increased the

target value of Mr. Read's long-term incentive compensation award

from $2 million to $3.5 million.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

99

Press release entitled "Pfizer Names Frank A. D'Amelio Chief Financial

Officer" dated August 22, 2007

10.1

Letter to Frank A. D'Amelio dated August 22, 2007 regarding his replacement

pension benefit

10.2

Severance Agreement between the Company and Frank A. D'Amelio dated August

22, 2007

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General Counsel and Corporate Secretary

Dated: August 22, 2007

EXHIBIT INDEX

Exhibit No.

Description

99

Press release entitled "Pfizer Names Frank A. D'Amelio Chief Financial

Officer" dated August 22, 2007

10.1

Letter to Frank A. D'Amelio dated August 22, 2007 regarding his replacement

pension benefit

10.2

Severance Agreement between the Company and Frank A. D'Amelio dated August

22, 2007